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Background: The association of EpCAM expression with the progression of gastric cancer remains unclear. Here,
we investigated the expression of EpCAM in gastric cancer subtypes and correlated the data to tumor cell
proliferation and clinicopathologic factors.
Methods: The intratumoral expression of EpCAM was assessed in 163 primary gastric cancers (61 diffuse-, 62 intestinal-,
32 mixed-type and 8 unclassified tumors) by immunohistochemistry, using the monoclonal antibody Ber-EP4. Intensity
of staining was classified according the HercepTest-score using a standardized scoring system. Ki-67 was used to
examine the proliferation in tumor tissue.
Results: Strong EpCAM expression was observed in 77% of the tumors and in 85% of the corresponding lymph nodes.
Of the primary tumors, 58% (n=74) presented a homogeneous intratumoral EpCAM expression while 42% were
characterised by a heterogenous expression pattern. Tumors with high EpCAM expression at the invasive front were
associated with significantly (p=0.03) higher proportion of lymph node metastases and lower median overall survival
(p=0.001). Diffuse type tumors presented a significantly higher EpCAM expression at the invasion front compared with
the tumor centre (p=0.036). Multivariate survival analysis identified high EpCAM expression at the invasive front as an
independent prognostic factor.
We observed a significant (p=0.001) correlation between high EpCAM expression and higher tumor cell proliferation.
Conclusion: High EpCAM expression associates with proliferation and progression of gastric cancer, especially in the
diffuse type. Considering the discontenting results of the current adjuvant concepts for gastric cancer patients, EpCAM
might be target in the adjuvant therapy of this malignant disease.
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Despite improvements in preoperative staging, surgical
techniques, and postoperative care, the outcome of pa-
tients with gastric cancer remains poor [1]. Although pa-
tients with stage I and II disease have 5 year survival rates
of 83–99% (stage I) and 48–70% (stage II) after curative
resection, the 5 year survival rate of patients with stage IV
gastric cancer is only 25% [2]. As a consequence,
multimodality therapy options have been established in
order to treat patients with locally advanced gastric cancer* Correspondence: nikolas.stoecklein@uni-duesseldorf.de
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reproduction in any medium, provided the or[3]. However, effective prognostic/predictive markers
identifying patients who might benefit from multimodal
therapy are currently not available.
The epithelial cellular adhesion molecule (EpCAM) is
a promising prognostic/predictive marker as well as an
interesting molecular therapeutic target. EpCAM is a
37–42 kDa type I transmembrane glycoprotein with two
epidermal growth factor like repeats in the external do-
main and a short intracellular domain containing of two
α-actin binding sites for actin cytoskeleton linkage [4,5].
Recent studies demonstrated that EpCAM is a potent
signal transducer that uses components of the Wnt
pathway, with an active involvement of EpCAM in cell
proliferation [6-8]. EpCAM is usually not expressed inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Intratumoral EpCAM expression in all study
patients
EpCAM expression
0 1+ 2+ 3+ Σ
patients 37 (23%) 52 (32%) 27 (17%) 47 (29%) 163
Primary tumor
pT1 3 (14%) 10 (48%) 4 (19%) 4 (19%) 21
pT2 22 (26%) 25 (29%) 15 (17%) 24 (28%) 86
pT3 10 (21%) 13 (27%) 7 (15%) 18 (38%) 48
pT4 2 (25%) 4 (50%) 1 (13%) 1 (13%) 8
Lymph node status
pN0 8 (20%) 13 (32%) 10 (24%) 10 (24%) 41
pN1 10 (19%) 19 (35%) 8 (15%) 17 (31%) 54
pN2 8 (29%) 10 (36%) 4 (14%) 6 (21%) 28
pN3 11 (28%) 10 (26%) 5 (13%) 13 (33%) 39
Tumor grade
G1 1 (50%) 0 (0%) 1 (50%) 0 (0%) 2
G2 5 (14%) 11 (31%) 8 (22%) 12 (33%) 36
G3 30 (25%) 40 (33%) 18 (15%) 34 (28%) 122
G4 1 (33%) 1 (33%) 0 (0%) 1 (33%) 3
Laurén classification
diffuse 20 (33%) 15 (25%) 9 (15%) 17 (28%) 61
intestinal 8 (13%) 21 (34%) 13 (21%) 20 (32%) 62
mixed 7 (22%) 12 (38%) 4 (13%) 9 (28%) 32
not classified 2 (25%) 4 (50%) 1 (13%) 1 (13%) 8
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frequently in gastric cancer [4]. In most tumor entities
de novo and/or high EpCAM expression correlates with
poor prognosis, conflicting data were published on the
prognostic impact of EpCAM in gastric cancer [9,10].
In this immunohistochemical study of a large collection
of gastric cancers we focussed on the relation between
EpCAM expression and the Lauren classification system
(morphology/differentiation) to further assess the potential
role of EpCAM in different biological processes, including
proliferation and differentiation, [6,9]. To additionally test
the potential impact of EpCAM expression levels on prolif-
eration, we stained consecutive sections of tumor tissues
with the proliferation marker Ki-67 and correlated the
staining data. Finally, we investigated the relation of the ex-
pression of EpCAM with clinicopathological factors and its
impact on prognosis in gastric cancer.
Results
EpCAM expression in gastric normal mucosa and cancer
As described previously [4], no expression of EpCAM
was observed in normal gastric mucosa of all patients
studied (100%, n=129). De novo expression of EpCAM
could be observed in 77% (n=126) of gastric cancers. A
strong (3+) EpCAM expression was found in 47 cases
(29%), moderate (2+) expression in 27 cases (17%), and
weak (1+) expression in 52 cases (32%) (Table 1). Absence
of EpCAM was observed in 37 gastric cancer cases (23%).
Representative examples of the abovementioned staining
levels of EpCAM in gastric cancers are shown in Figure 1.
In 42% of the study patients (n=54), we observed a dif-
ferential EpCAM expression pattern with respect to the
centre and the invasion front of the tumor. Tumors with
higher EpCAM expression in the invasion front were as-
sociated with a significantly higher proportion of lymph
node metastases (p=0.03; Table 2), whereas no signifi-
cant correlations could be observed between EpCAM
expression and pT-category, grading, or gender. Diffuse
type gastric cancers exhibited a significantly weaker
overall EpCAM expression than intestinal type cancers
(p=0.008) or mixed type cancers (Figure 2A; Table 1).
Under consideration of the Lauren-Classification we
could observe that mixed type tumors were presented
with the highest proportion of homogeneous EpCAM
expression pattern (62.5% homogeneous, 37.5% hetero-
geneous). In contrast in diffuse and intestinal types of
tumors 55% were presented with homogeneous and 45%
heterogeneous EpCAM expression pattern. Focussing
only the heterogenic expression pattern of 45%, we no-
ticed that 28% of diffuse type of tumor was presented
with higher EpCAM expression in the invasion front
while the rest of 17% was presented with higher EpCAM
expression in the tumor centre. In intestinal type tumors
the EpCAM expression was high in the invasion front in14% while 31% of the tumors exhibited high EpCAM ex-
pression in the tumor centre. Statistical analysis revealed
that diffuse type gastric cancers were characterised by
significantly (p=0.036) higher EpCAM expression in the
invasion front (28%) than in the tumor centre compared
to the intestinal type; (Figure 2B).
Expression of EpCAM in lymph node metastases of
gastric cancer
Lymph node metastases of 88 cases were available for the
analysis. Eighty-five percent (n=75) of lymph node metas-
tases were positive for EpCAM. EpCAM-positivity of
lymph node metastases was significantly correlated with
EpCAM-positive primary tumors (p<0.001; Figure 3).
Moreover, primary tumors with EpCAM-positive lymph
node metastases displayed an advanced depth of tumor in-
vasion (pT3/4) (p=0.046).
KI-67 expression and its correlation to the expression of
EpCAM
KI-67 positive nuclei were counted in 92% (n=147/160) of
all gastric cancer samples with a median of 7% of
KI-67-positive nuclei (range 0 to 60%). After classification
into “high” proliferation (> 7% positive nuclei) and “low”
Figure 1 Examples of different staining levels of EpCAM in gastric cancer (A: EpCAM 0; B: EpCAM 1+; C: EpCAM 2+; D: EpCAM 3+).
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dian proliferation rate, we observed a low proliferation
rate in 57% and a high proliferation rate in 43% of the
cases. Correlating EpCAM expression with KI-67-positive
tumor cell nuclei using linear regression, we observed a
significant positive correlation in primary tumor samples
(p<0.006) as well as in lymph node metastases (p=0.02)
(Figure 4). Figure 5 presents EpCAM expression in gastric
cancer with corresponding Ki67 expression.
Prognostic influence of EpCAM expression
For survival analysis, 135 patients could be included
with a median observation time of 26 months (range
1–171 months). pT-, pN- category, and UICC-stage




homogeous expression pattern 18 24% 56 76% p = 0,065
heterogeous expression pattern 6 11% 47 89%
tumor center > invasion front 5 61% 25 39% p = 0,169
invasion front > tumor center 1 4% 22 96%
invasion front > tumor center 1 4% 22 96% p = 0,037
rest 23 22% 81 78%p<0.001), while gender, age, Laurén classification and
grading showed no prognostic impact.
When comparing EpCAM negative tumors with EpCAM
positive tumors, no significant correlation with overall sur-
vival was detected. The median cumulative survival was 20
months for EpCAM negative tumors and 24 months for
patients with EpCAM positive tumors (log rank, p=0.765).
In contrast, a heterogeneous EpCAM expression pattern
between the centre and invasion front of the tumor was
associated with a significant negative impact on survival
(log rank, p=0.04). The median cumulative survival time
of patients with an increased EpCAM expression in the
invasion front was the lowest with 11 months compared
with 29 months of patients with a homogeneous EpCAM
expression and 23 months in patients with EpCAM ex-
pression stronger within the tumor center (Figure 6).
When comparing the group of patients with a stronger
EpCAM expression in the invasion front with all other pa-
tients, we found a significant negative prognostic impact
(log rank, p=0.001). Performing multivariate analysis (cox-
regression), we demonstrated that this was an independ-
ent prognostic factor for overall survival (Table 3).
Discussion
This study investigated the expression pattern of
EpCAM and its prognostic value in gastric cancer. We
observed EpCAM expression in most of the gastric can-
cers, while it was absent in normal gastric epithelia.
Figure 2 EpCAM expression in different tumor compartments. A: EpCAM staining in gastric cancer according to Lauren-classification
B: Distribution (in %) of EpCAM staining pattern in diffuse and intestinal type gastric cancer. (Black = invasion front stronger than tumor center;
light grey = tumor center stronger than invasion front); p=0.036.
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patterns with respect to the centre and invasion front of
the tumor, which was identified as an independent prog-
nostic factor. Furthermore, our study disclosed a significant
correlation between high EpCAM expression and high
tumor cell proliferation, suggesting that EpCAM promotes
proliferation and progression of gastric cancer in vivo.
Although EpCAM belongs to the best studied cancer-
associated antigens [11], its biological role in tumorigen-
esis is still not fully understood. While in some cancer
types, including renal cell and thyroid cancer, EpCAM ex-
pression is associated with an improved survival, in other
tumors high intratumoral EpCAM expression was identi-
fied as a poor prognostic factor [9,12-15]. Such controver-
sial findings may have various biological reasons including
the possibility of differing functions of EpCAM across or-
gans and affected tissues. In this respect it is important to
note that EpCAM is a potent signal transducer, whichuses components of the Wnt pathway and which is causa-
tively involved in the regulation of proliferation and cell
cycle progression [5,7,16,17]. Regulatory functions of
EpCAM however require regulated intramembrane prote-
olysis, and thus proteases, and interaction partners, which
might represent limiting factors in some organs.
It is however puzzling to realise that even in the same
entity, i.e. in gastric cancer, conflicting data on the prog-
nostic impact of EpCAM were published [9,10]. For ex-
ample, Songun et al. demonstrated in 300 gastric cancer
patients that 93% were EpCAM positive and loss of ex-
pression identified aggressive tumors, especially in pa-
tients with stage I and II disease [18]. In contrast, in-vitro
and in-vivo analyses by Du et al. showed that protein ex-
pression of EpCAM is higher in metastatic than in non-
metastatic gastric cancers [10]. Similar findings were
reported by Wenqi et al. in gastric cell lines and tumor tis-
sues. The authors revealed that EpCAM is overexpressed in
Figure 3 EpCAM staining in lymph node metastases and corresponding primary tumors (light grey=EpCAM-negative lymph node
metastasis; black=EpCAM-positive lymph node metastasis).
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decrease of cell proliferation and suppressed tumor forma-
tion [19]. One of the possible reasons to explain these differ-
ent findings might be intratumoral heterogeneity of gastric
carcinomas that was observed in our study. Obviosly, the
different non-standardized immuno-histochemical methods
and staining evaluations used in the different studies might
also explain these discrepancies. Therefore we tried to use a
relatively standardized scoring system the HercepTest
(Dako), to classify the EpCAM expression. Using this sys-
tem, we identified 77% of gastric carcinomas exhibiting deFigure 4 Linear regression analysis of Ki-67 positive nuclei (%
of tumor tissue) in correlation to the Hercep-Score of the
EpCAM staining for primary tumor tissue and lymph node
metastasis. The slope of line for the primary tumor samples (n=163)
was 24.64 [95% confidence interval (CI), 16.4 to 32.89] and the
correlation coefficient (r2) 0.9881. For lymph node samples (n=88)
the slope of the line was 3.466 [95% CI, 1.299 to 5.633] and the r2
0.9595. The dots/squares illustrate the mean value and the error bars
the standard error of the mean (SEM). The slope of the lines
deviated both significantly from zero (primary tumor: p=0.006;
lymph node metastasis: p=0.02).novo expression of EpCAM within the primary tumor, while
normal gastric mucosa was devoid of EpCAM. These results
are consistent with the findings reported by Songun et al.
and Wenqi et al. However, while these authors were able to
demonstrate a prognostic difference between EpCAM nega-
tive and positive tumors, we did not observe such a correl-
ation. Interestingly, we found in 42% of our study patients
differential EpCAM expression patterns when comparing
the tumor centre with the invasion front. Tumors with
higher EpCAM expression at the invasive front, exhibited a
significantly higher proportion of lymph node metastases
and a significantly decreased overall survival, which was of
independent prognostic impact. Comparably, Gonsens et al.
described a significant correlation between EpCAM staining
at the invasive margin of rectal tumor specimens and tumor
budding, tumor grade and an increased risk of local recur-
rence for the case of colorectal cancer [20]. Based on our
findings, one might speculate about a differential intratumoral
status of activation of EpCAM with a different expression pat-
tern in invasion front and tumor center. On the other hand
this difference seems not to be homogeneous in gastric can-
cer. This hypothesis has to be validated in further studies.
Moreover, we noticed in our study differential EpCAM
expression patterns in the diverse types of gastric can-
cers according to the classification by Lauren. Similar
findings have been shown by Joo et al. [21], who ob-
served a correlation between intratumoral EpCAM
over-expression and Lauren classification and histo-
logic grading in gastric cancer patients.
As mentioned above, so far, the exact mechanisms of
EpCAM contributing to the malignant potential of
tumor cells are not entirely understood. In vivo experi-
ments provided the first evidence of a direct link be-
tween EpCAM and cell cycle control. In fact, Chaves-
Perez et al. recently showed that upon intratumoral
EpCAM overexpression c-myc is rapidly upregulated [8].
Figure 5 Example of A: EpCAM expression with corresponding B: Ki67 expression.
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factor requirement, enhanced metabolic activity and col-
ony formation capacity. Importantly, expression of
EpCAM anti-sense mRNA reversed these actions and
led to a substantial decrease in proliferation and metab-
olism [22]. Furthermore, Maetzel et al. revealed that sig-
nalling by EpCAM requires regulated intramembrane
proteolysis to release its intracellular domain EpICD. Re-
leased EpICD associates with components of the Wnt
pathway, regulates gene transcription in the nucleus and,
finally, cell proliferation and tumor formation [6]. Our
study results are in agreement with these findings. In
fact, we found that intratumoral EpCAM expression sig-
nificantly correlates with Ki-67 expression, a nuclear
proliferation associated antigen expressed in the growth
and synthesis phase of the cell cycle [23]. These data
suggest a higher proliferative activity in EpCAM positive
cancer cells and an important role of EpCAM in cellFigure 6 Survival analysis according to different EpCAM
expression patterns in gastric cancer patients.cycle control as demonstrated in vitro by the tight regu-
lation of cyclin D1 by EpCAM [8].
EpCAM expression might be also exploited for
EpCAM-directed therapies. Just recently Ströhlein et al.
performed an open-label, multicenter, phase I/II trial
about the immunotherapy of peritoneal cancerosis with
the antibody catumaxomab in gastric cancer [24]. In
EpCAM-positive tumors catumaxomab, an antibody that
specifically binds EpCAM-positive tumor cells and CD3+
T-lymphocytes, showed an acceptable safety profile and
promising treatment efficiency, suggesting EpCAM to be
an important target in the therapy of gastric cancer. Our
results support these findings.
The present study provides some limitations. The rela-
tionship between intratumoral EpCAM expression and
other known prognostic factors, such as lymphovascular
invasion and serum CEA and CA19-9 would elevate the
impact of this study. However this data were not avail-
able in the data base and could not be considered.
Conclusion
We observed that high EpCAM expression is associated
with increased proliferation and poor prognosis. Consid-
ering the discontenting results of the current (neo-) ad-
juvant concepts for gastric cancer patients, additional
therapeutic EpCAM-targeting might be a beneficial con-
cept for multimodality therapy of this malignant disease.
Our findings are hypothesis generating and should be
validated in larger clinical trials.
Methods
Tissue samples and clinical data
Paraffin-embedded tissue samples of 163 patients with
gastric cancer were obtained from the institute of path-
ology for immunohistochemical analysis. The specimens
were previously fixed in 10% formaldehyde, according to
established methods [25]. There were 108 (65%) male
and 57 (35%) female patients with a median age of 70
years (range 34–91).
Table 3 Univariate and multivariate survival analyses
Univariate analysis Multivariate analysis
Category n Deaths % Alive Mean survival (month) 95% CI p-value Relative risk 95% CI p-value
Age
>70 71 46 35.2% 35 5.85-64.14 0.24
≤ 70 64 46 35.2% 23 13.4-32.57
Gender
male 89 64 29.1 23 14.64-31.32 0.14
female 46 28 39.1 51 3.1-98.83
pT-category
T1+2 98 61 62.2 56 16.21-95.78 0.000 2.0 1.2-3.2 0.003
T3+4 37 31 16.2 11 7.03-14.96
pN-category
N0 40 20 50 29.4 51.36-166.63 0.001 2.3 1.2-4.4 0.01
N1-3 95 72 24.2 2.6 14.09-25.0
Grading
G1+2 35 20 42.9 77 19.48-134.51 0.14
G3+4 100 72 28 24 15.70-32.29
EpCAM Expr.
EpCAM IF+ 20 19 5 11 0.0-24.14 0.001 2.0 1.2-3.5 0.008
Other exp. pattern 85 58 31.8 26 16.97-35.03
Table 4 Tumor characteristics of the 163 study patients
n %









Metastases M0 154 94%
M1 9 6%




Laurén classification diffuse 61 37%
intestinal 62 38%
mixed 32 20%
not classified 8 5%
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department. Tumor grading was performed according to
World Health Organization (WHO) standards and
according to Laurén-classification. The samples were
randomly selected by experienced pathologists (S.E.B
and H.G.) from the archives of the Department of Path-
ology of the University Hospital Duesseldorf based on
availability of the follow up data. All patients underwent
curative surgery at the University Hospital Duesseldorf
between 1995 and 2006. Patients with neoadjuvant ther-
apy were excluded from the cohort. Overall survival data
were retrieved from a prospectively maintained clinical
data-base of our hospital. Information about adjuvant
therapy was not provided in this data base. Patients with
metastasis, incomplete resection (R1) and/or incomplete
data were not considered in the overall survival analysis.
Tumor characteristics are summarised in Table 4.Ethics statement
This study was approved by the Ethics Committee of the
Medical Faculty of the Heinrich-Heine University Düsseldorf.Table 5 HercepTest-Score for the quantification of EpCAM
expression
0 0-10% stained cells
1+ >10% weakly stained cells
2+ >10% moderately stained cells
3+ >10% strongly stained cells
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Nine TMA-blocks were constructed, in which up to six
tissue sample cylinders from 20 patients were arranged
on one paraffin block. Two cylinders were chosen from
the tumor centre, two from the invasion front, one sam-
ple of normal mucosa and one from a lymph node
lymph node metastasis if available. For the tissue cylin-
ders, a diameter of 1.0 mm was taken from representa-
tive areas of the donor blocks and transferred to the
recipient TMA-blocks with interspaces of 2.5 mm be-
tween each tissue cylinder. In total, 835 (93%) tumor
biopsies were analyzed.Immunochemistry
4 μm slides of each tissue microarray block were cut for
immunhistochemical stainings. After deparaffinisation with
xylol (Merck, 1.08685.2500; 3×10 minutes) and ethanol
(99.5%, 2×5 minutes; 96%, 2×5 minutes; 80%, 2×5 minutes;
70% 1×5 minutes), epitopes were retrieved with Dako tar-
get retrieval solution at 95°C for 30 minutes and cooled
down for another 20 minutes. Endogenous peroxidase was
inactivated using 0.3% H2O2-PBS for 30 min at room
temperature. Subsequently, sections were rinsed twice for
five minutes in phosphate buffered saline (PBS, pH 7.4).
Immunostaining was performed with antibodies directed
against EpCAM (Ber-EP4, 2 μg/ml, Dako Cytomation,
USA) and Ki-67 (mouse monoclonal, Dako Cytomation,
USA, 1 μg/ml). Incubation with the primary antibodies was
performed at room temperature for 30 min. The Vectastain
ABC peroxidase kit was used following the manufacturer’s
instructions (Vector Lab, USA) to visualize specific anti-
body binding. Isotype controls using IgG1 (MOPC-21,
2 μg/ml, Dako Cytomation, USA) were performed on serial
sections of each sample. Diaminobenzidine (Liquid DAB,
Dako Cytomation, USA) was used to stain the bound
immuno-complex. All specimens were counterstained with
haematoxylin (Sigma, Deisenhofen).Evaluation of immunhistochemical staining
Two independent researchers (AD, NHS) examined the
sections. Differing results were discussed with a senior
pathologist (SEB) and a consensus decision was made.
Normal colonic mucosa was used as an internal control for
staining efficiency. First, EpCAM staining intensity was
classified according to the percentage of positive-stained
cells into categories from 0 (no expression) to 3+ (strong
expression) (Table 5). Then, tissue samples were classified
according to the HercepTest™ (Dako) [26], a scoring system
developed for the evaluation of p185HER-2-expression,
which we applied for the evaluation of EpCAM expression
[27,28]. Using this score, tumor specimens could be divided
into four groups. The median of KI-67-positive tumor cell
nuclei of all specimens was used to distinguish low(<7% positive nuclei) from high (>7% positive nuclei)
proliferation.
Statistical analysis
Statistical analysis was performed with the SPSS software
(SPSS Standard version 17.0.0, SPSS Inc., Chicago, IL).
P-values smaller than 0.05 (p<0.05) were considered sta-
tistically significant. Clinicopathological data were di-
chotomized. The χ2-test and the Fisher’s exact test were
used to analyse the difference in the frequency of
EpCAM-expression in relation to histopatholgical pa-
rameters. One-hundred-and-thirty-six patients were
eligible for the analysis of overall survival. Survival
curves were plotted according to Kaplan-Meier, univariate
association was determined using the log-rank-test. Cox-
Regression was performed to identify the independency of
prognostic factors in a multivariate analysis.
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